Education
About Us
Working with TipRanks
Follow Us
Eyepoint Pharma (DE:PV3B)
:PV3B
RESEARCH TOOLSreports
PV3B Stock Chart & Stats
Day’s Range― - ―
52-Week Range€5.16 - €21.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€370.30M
Enterprise Value€204.47M
Total Cash (Recent Filing)$3.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Apr 30, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding68,728,760
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.83
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
€30.77Price Target Upside496.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
EyePoint Pharmaceuticals News
PremiumCompany Announcements
EyePoint Pharma’s Earnings Call: Clinical Progress Amid Financial Challenges
PremiumCompany Announcements
EyePoint Pharmaceuticals Reports 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment in both Phase 3 LUGANO and LUCIA studies for Duravyu in wet AMD is going faster than expected.
Product PotentialDuravyu is seen as a potential best-in-class product that may reduce the treatment burden in retinal diseases, addressing a significant unmet medical need in wet AMD.
ValuationThe stock is considered significantly undervalued, presenting a positive risk/reward scenario.
Bears Say
Financial PerformanceFor 4Q24, net loss was $41.4M, which was more than the estimated loss of $29.4M.
Investor ConcernsInitial press release lacked detail from the control arm, which likely left some investors concerned.
---
Options Prices
Currently, No data available
---
Ownership Overview
13.16% Insiders
19.18%
Mutual Funds
0.23% Other Institutional Investors
56.91% Public Companies and
Individual Investors
PV3B FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was €5.16 and its highest was €21.25 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is €370.30M.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Apr 30, 2025 which is in 28 days.
How were Eyepoint Pharma’s earnings last quarter?
Eyepoint Pharma released its earnings results on Mar 05, 2025. The company reported -€0.595 earnings per share for the quarter, missing the consensus estimate of -€0.451 by -€0.143.
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.62.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 68,728,760 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Eyepoint Pharma reported an EPS of -€0.595 in its last earnings report, missing expectations of -€0.451. Following the earnings report the stock price went up 6.717%.
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in DE:PV3B
---
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€30.77 (496.22% Upside)
€30.77 (496.22% Upside)
Blogger Sentiment
Bullish
DE:PV3B Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.77%
12-Months-Change
Fundamentals
Return on Equity
-43.42%
Trailing 12-Months
Asset Growth
17.82%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
---
PV3B Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and a strong financial position, which were tempered by a decrease in revenue and increased operating expenses leading to a greater net loss. The advancements in clinical trials and robust financial backing are promising, yet the financial performance indicates some challenges.Read More>---
PV3B Stock 12 Month Forecast
Average Price Target
€30.77
▲(496.22% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Editas Medicine
―
Kala Pharmaceuticals
―
Best Analysts Covering PV3B
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
+32.89%
reiterated a buy rating 2 months ago
Copying Jennifer Kim's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +32.89% per trade.
---